HIV/AIDS Therapy
HIV phenotypic/genotypic markers of resistance evaluated at virologic failure
Published in Blood Weekly, October 28th, 2004
"We evaluated phenotypic and genotypic markers of drug resistance in human immunodeficiency virus type 1 (HIV-1) at the time of virologic failure (VF) in subjects in the AIDS Clinical Trials Group Protocol 388 (ACTG 388) who received lamivudine-zidovudine (or lamivudine-stavudine) and either indinavir, efavirenz-indinavir, or nelfinavir-indinavir," researchers in the United States report.
"At VF, phenotypically susceptible HIV-1 was found in 55% of subjects in the nelfinavir-indinavir arm, compared with 22% in the indinavir arm (P=0.006). Phenotypic resistance to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-10-28)
More Articles from Blood Weekly
- Cord Blood
Umbilical cord blood transplant after nonmyeloablative conditioning is promising - Hemophilia
Viruses bearing transgene generate coagulation factor in hemophilia A models - Liver Regeneration
Fluidized bed bioreactor has potential for extracorporeal liver supply - Non-Hodgkin Lymphoma
Allogeneic blood transfusion does not increase risk of non-Hodgkin lymphoma - Obstetrics
Diagnosis and management of twin-twin transfusion syndrome reviewed - Tissue Engineering
Novel scaffolds may be very useful for vascular tissue engineering - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
